Question: after implementing FDA 21 CFR Section 11 rule by the company for not identifying the black spots in the API of the final product intially
after implementing FDA 21 CFR Section 11 rule by the company for not identifying the black spots in the API of the final product intially so what will be the next implemented for patients,the clinical trail individuals and also next for New drug application ?
Step by Step Solution
There are 3 Steps involved in it
1 Expert Approved Answer
Step: 1 Unlock
Question Has Been Solved by an Expert!
Get step-by-step solutions from verified subject matter experts
Step: 2 Unlock
Step: 3 Unlock
